Literature DB >> 22134155

Experimental mouse tumour models: what can be learnt about human cancer immunology?

Glenn Dranoff1.   

Abstract

The recent demonstration that cancer immunotherapy extends patient survival has reinvigorated interest in elucidating the role of immunity in tumour pathogenesis. Experimental mouse tumour models have provided key mechanistic insights into host antitumour immune responses, and these have guided the development of novel treatment strategies. To accelerate the translation of these findings into clinical benefits, investigators need to gain a better understanding of the strengths and limitations of mouse model systems as tools for deciphering human antitumour immune responses.

Entities:  

Mesh:

Year:  2011        PMID: 22134155     DOI: 10.1038/nri3129

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  60 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Bioluminescent imaging of melanoma in live mice.

Authors:  Noah Craft; Kevin W Bruhn; Bidong D Nguyen; Robert Prins; Linda M Liau; Eric A Collisson; Abhijit De; Michael S Kolodney; Sanjiv S Gambhir; Jeff F Miller
Journal:  J Invest Dermatol       Date:  2005-07       Impact factor: 8.551

3.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

4.  Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Authors:  Celestia S Higano; Paul F Schellhammer; Eric J Small; Patrick A Burch; John Nemunaitis; Lianng Yuh; Nicole Provost; Mark W Frohlich
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

Review 5.  GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.

Authors:  Vincent G Brichard; Diane Lejeune
Journal:  Vaccine       Date:  2007-09-27       Impact factor: 3.641

6.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Authors:  Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

7.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

8.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Authors:  Bin Zhang; Theodore Karrison; Donald A Rowley; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis.

Authors:  Tiziana Schioppa; Robert Moore; Richard G Thompson; Elizabeth C Rosser; Hagen Kulbe; Sergei Nedospasov; Claudia Mauri; Lisa M Coussens; Frances R Balkwill
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

View more
  42 in total

Review 1.  New cast for a new era: preclinical cancer drug development revisited.

Authors:  Grit S Herter-Sprie; Andrew L Kung; Kwok-Kin Wong
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

3.  Immunotherapy at large: Balancing tumor immunity and inflammatory pathology.

Authors:  Glenn Dranoff
Journal:  Nat Med       Date:  2013-09       Impact factor: 53.440

Review 4.  Neutrophils: Critical components in experimental animal models of cancer.

Authors:  Catharina Hagerling; Zena Werb
Journal:  Semin Immunol       Date:  2016-03-11       Impact factor: 11.130

5.  Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.

Authors:  Katherine A Waugh; Sonia M Leach; Brandon L Moore; Tullia C Bruno; Jonathan D Buhrman; Jill E Slansky
Journal:  J Immunol       Date:  2016-07-01       Impact factor: 5.422

Review 6.  Regulatory considerations for clinical development of cancer vaccines.

Authors:  Bridget Theresa Heelan
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

8.  Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.

Authors:  Allan NoeDominguez-Romero; Rubén Zamora-Alvarado; Rodolfo Servín-Blanco; Erendira G Pérez-Hernández; Laura E Castrillon-Rivera; Maria Elena Munguia; Gonzalo Acero; Tzipe Govezensky; Goar Gevorkian; Karen Manoutcharian
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  Mouse models for studying angiogenesis and lymphangiogenesis in cancer.

Authors:  Lauri Eklund; Maija Bry; Kari Alitalo
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

Review 10.  Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era.

Authors:  Everett J Moding; Yvonne M Mowery; David G Kirsch
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.